Disparities in outcomes of pancreatic cancer hospitalizations: A ten-year trend study. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not ...

Toxicology and clinical protocol development of DUO-207: An ultrasmall nanomedicine co-delivering gemcitabine and paclitaxel for the treatment of metastatic pancreatic cancer. This is an ASCO Meeting ...

Approximately 30% of pancreatic cancer patients present with locally unresectable disease with no evidence of distant metastases. Local control in this patient population can provide effective ...

The long-term survival of patients is dependent upon the complete macroscopic resection of the tumor (R0, R1). [53] Patients with grossly incomplete resections (R2) survive less than 1 year, [11 ...

The San Francisco biotech confirmed that neither the PanCAN Precision Promise study in metastatic pancreatic cancer nor the LAPIS trial in patients with locally advanced, unresectable pancreatic ...

The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 ...

Cullen and colleagues conducted a prior trial for patients with unresectable pancreatic cancer, and three of the 14 patients survived beyond 9 years. “It was curative in three patients,” he said.

including safety and feasibility studies treating patients with pancreatic cancer, a combination study with pembrolizumab in patients with recurrent unresectable or metastatic HNSCC, and other ...

High disease control rate and strong interim safety results observed in pancreatic cancer patients across ... for recurrent unresectable or metastatic head and neck squamous cell carcinoma ...